This discovery implies that targeted microbial ablation holds promise as an effective strategy to surmount the constraints of pharmacological inhibition, addressing the intricate dynamics of the signaling of IL‐17A and its receptor (IL‐17RA) across various compartments in the context of the cancer therapy. The gene discussed is IL17A; the disease is cancer.